




## Solitary pink papule in an elderly man



Asma Amir Ali, MD,<sup>a</sup> Meer-Taher Shabani-Rad, MD,<sup>b</sup> and Justin C. Chia, MD<sup>a</sup>  
*Calgary, Alberta, Canada*

**Key words:** 6p25.3; CD-30 lymphoproliferative disorder; dermoscopy; DUSP22-IR4; lymphomatoid papulosis.





A 72-year-old, healthy man presented with an asymptomatic, stable, solitary, 5-mm × 5-mm, pink, dome-shaped papule on his neck that had been present for at least 6 months (Fig 1). There were no identifiable triggers, including exposure to drugs, radiation, or trauma to that area. A physical examination was unremarkable and did not demonstrate lymphadenopathy or hepatosplenomegaly. Polarized dermoscopy demonstrated a homogeneous, pink papule with serpentine, dotted, and short linear vessels; white, shiny lines; and white rosette structures (Fig 2). Pathology showed a heavy infiltrate of intermediate-to-large, atypical lymphoid cells involving the papillary dermis, dermoepidermal junction, and epidermis. The atypical lymphoid cells monotonously stained for CD3, diffusely expressed CD30 and nuclear MUM1 (bright), and were double-negative for CD4 and CD8 (Figs 3 and 4). ALK-1, SOX10, PD1, and CD138 were negative. No further investigations were undertaken.

**Question 1: Given the history and images, what is the most likely diagnosis?**

- A. Primary cutaneous anaplastic large cell lymphoma with 6p25.3 rearrangement
- B. Transformed CD30<sup>+</sup> mycosis fungoides (MF)
- C. Lymphomatoid papulosis (LyP) with 6p25.3 rearrangement (LyP 6p25.3)
- D. LyP type C
- E. LyP type B

**Answers:**

**A.** Primary cutaneous anaplastic large cell lymphoma with 6p25.3 rearrangement – Incorrect. Histologically, this entity can also present with a nodular dermal infiltrate of CD30<sup>+</sup>, atypical lymphoid cells but no evidence of epidermal involvement of CD30<sup>+</sup> cells, which is one of characteristic features of this subtype of LyP.<sup>1,2</sup> The 6p25.3 rearrangement on the *DUSP22* locus has been correlated with the inhibition of tumor suppression.<sup>3</sup>

**B.** Transformed CD30<sup>+</sup> MF – Incorrect. This patient had no prior diagnosis of MF, and MF does not usually present with one solitary papule on the head and neck region.

**C.** LyP 6p25.3 – Correct. This entity was first reported by Karai et al<sup>4</sup> in 2013. It usually presents in men, at a mean age of 75, as one or a few papulonodules at a single site. Pathology reveals a dermal nodule composed of lymphocytes with

overlying CD30<sup>+</sup>, MUM1<sup>+</sup>, atypical lymphocytes in the epidermis, resembling pagetoid reticulosis.<sup>2,4</sup> In general, surveillance is recommended for patients with LyP given the risk for developing secondary lymphomas; however, Karai et al<sup>4</sup> did not note the development of lymphomas in any of their patients.

**D.** LyP type C – Incorrect. LyP type C shares certain histologic features of LyP with 6p25.3 rearrangement, such as nodular infiltrates in lymphocytes; however, CD4 and TIA1 are usually also expressed.<sup>2,4</sup> The epidermal involvement of CD30<sup>+</sup> lymphoid cells is not a characteristic feature of LyP type C. Clinically, it presents at a mean age of 38 and is typically characterized by disseminated papulonodules.<sup>4,5</sup>

**E.** LyP type B – Incorrect. The epidermal findings of LyP 6p25.3 are similar to those of LyP type B; however, LyP type B expresses CD4 and has more of a band-like dermal lymphocytic infiltrate with no evidence of the epidermal involvement of CD30<sup>+</sup> lymphoid cells.<sup>2,4,5</sup>

**Question 2: What is the common immunohistochemical staining pattern found in LyP with a 6p25.3 rearrangement?**

- A. CD3<sup>+</sup>, CD30<sup>+</sup>, MUM1<sup>+</sup>, ALK<sup>-</sup>, CD4, and CD8 are often (but not always) negative
- B. CD30<sup>+</sup>, CD4<sup>+</sup>, ALK<sup>-</sup>, EMA<sup>-</sup>, CLA<sup>+</sup>
- C. CD4<sup>+</sup>, CD8<sup>-</sup>, CD30<sup>+/-</sup>
- D. CD4<sup>+</sup>, CD8<sup>-</sup>, CD30<sup>+</sup>

From the Division of Dermatology, Department of Medicine<sup>a</sup> and Department of Pathology and Laboratory Medicine, University of Calgary.<sup>b</sup>

Funding sources: None.

IRB approval status: Not applicable.

Correspondence to: Justin C. Chia, MD, Division of Dermatology, Department of Medicine, University of Calgary, #225, 600 Crowfoot Crescent NW, Calgary, AB, Canada T3G 0B4. E-mail: [justin.chia@albertahealthservices.ca](mailto:justin.chia@albertahealthservices.ca).

JAAD Case Reports 2022;24:48-51.

2352-5126

© 2022 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<https://doi.org/10.1016/j.jidcr.2022.04.004>

**E.** CD4<sup>+</sup> greater than CD8<sup>+</sup>, CD30<sup>+/-</sup>, CD3<sup>-</sup>, CD7<sup>-</sup>

**Answers:**

**A.** CD3<sup>+</sup>, CD30<sup>+</sup>, MUM1<sup>+</sup>, ALK<sup>-</sup>, CD4, and CD8 are often (but not always) negative – Correct. A review of 11 patients with LyP 6p25.3 showed this pattern most often.<sup>4</sup> Of note, the CD30 stain is more prominent in the dermis than in the epidermis in most reported cases; this was seen in our patient as well (Fig 4).<sup>2,4</sup>

**B.** CD30<sup>+</sup>, CD4<sup>+</sup>, ALK<sup>-</sup>, EMA<sup>-</sup>, CLA<sup>+</sup> – Incorrect. This is the staining pattern for primary cutaneous anaplastic large cell lymphoma.<sup>6</sup>

**C.** CD4<sup>+</sup>, CD8<sup>-</sup>, CD30<sup>+/-</sup> – Incorrect. This is the staining pattern for LyP type B.<sup>6</sup>

**D.** CD4<sup>+</sup>, CD8<sup>-</sup>, CD30<sup>+</sup> – Incorrect. This is the staining pattern for LyP type C.<sup>6</sup>

**E.** CD4<sup>+</sup> greater than CD8<sup>+</sup>, CD30<sup>+/-</sup>, CD3<sup>-</sup>, CD7<sup>-</sup> – Incorrect. This is the staining pattern for transformed MF.

**Question 3: Which of the following is a dermoscopic pattern for LyP 6p25.3?**

**A.** A white, structureless area surrounding tortuous vessels that extends centrifugally

**B.** A central, white, structureless area with vessels present on the periphery

**C.** Vessels surrounding an area of necrosis and ulceration

**D.** A brown-gray, structureless area with no vessels

**E.** Linear, curved, and tortuous vessels; rosettes; and shiny, white lines

**Answers:**

**A.** A white, structureless area surrounding tortuous vessels that extends centrifugally – Incorrect. This pattern is seen in the initial stage of more common forms of LyP.<sup>5,7</sup>

**B.** A central, white, structureless area with vessels present on the periphery – Incorrect. This pattern is seen with more mature lesions of more common forms of LyP.<sup>5,7</sup>

**C.** Vessels surrounding an area of necrosis and ulceration – Incorrect. This pattern is seen in more common forms of LyP prior to the cicatricial phase.<sup>5,7</sup>

**D.** A brown-gray, structureless area with no vessels – Incorrect. This pattern is seen with scarring or postinflammatory dyspigmentation in more common forms of LyP.<sup>5,7</sup>

**E.** Linear, curved, and tortuous vessels; rosettes; and shiny, white lines – Correct. To our knowledge, this pattern has not yet been described, and it was seen in our patient with LyP with 6p25.3 gene rearrangement.

**Abbreviations used:**

LyP: lymphomatoid papulosis

LyP 6p25.3: lymphomatoid papulosis with 6p25.3 rearrangement

MF: mycosis fungoides

**Conflicts of interest**

None disclosed.

**REFERENCES**

1. Feldman AL, Grogg KL, Knudson RA, Inwards DJ. Secondary cutaneous involvement by systemic anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma with 6p25.3 rearrangement. *Histopathology*. 2015;67(6):932-935. <https://doi.org/10.1111/his.12729>
2. Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. *Blood*. 2019;133(16):1703-1714. <https://doi.org/10.1182/blood-2018-11-881268.4>
3. Mélard P, Idrissi Y, Andrique L, et al. Molecular alterations and tumor suppressive function of the DUSP22 (dual specificity phosphatase 22) gene in peripheral T-cell lymphoma subtypes. *Oncotarget*. 2016;7(42):68734-68748. <https://doi.org/10.18632/oncotarget.11930>
4. Karai LJ, Kadin ME, Hsi ED, et al. Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. *Am J Surg Pathol*. 2013;37(8):1173-1181. <https://doi.org/10.1097/PAS.0b013e318282d01e>
5. Martinez-Cabrales SA, Walsh S, Sade S, Shear NH. Lymphomatoid papulosis: an update and review. *J Eur Acad Dermatol Venereol*. 2020;34(1):59-73. <https://doi.org/10.1111/jdv.15931>
6. Stoll JR, Willner J, Oh Y, et al. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part I: clinical and histologic features and diagnosis. *J Am Acad Dermatol*. 2021;85(5):1073-1090. <https://doi.org/10.1016/j.jaad.2021.04.080>
7. Moura FN, Thomas L, Balme B, Dalle S. Dermoscopy of lymphomatoid papulosis. *Arch Dermatol*. 2009;145(8):966-967. <https://doi.org/10.1001/archdermatol.2009.167>